Stand Up To Cancer, also known as SU2C, is a privately owned entity headquartered in the US that functions as a tier 2 media tech buyer. Founded in 2008, the organization has approximately 60 employees and reported $38.1M in revenue as of 2023. The company's main product involves content rights, and its mission focuses on raising funds to accelerate groundbreaking translational research to develop new therapies for patients and save lives.
On March 27, 2026, AbbVie announced a multi-year partnership with Major League Baseball (MLB), becoming the Official Pharmaceutical Partner of MLB starting with the 2026 season. This first-of-its-kind partnership for AbbVie nationally expands the "Striking Out Cancer" initiative, which the company initially launched during the 2025 MLB season through its collaboration with the Chicago Cubs. Previously, on January 8, 2026, Stand Up To Cancer (SU2C) and Cancer Research UK announced new support for a global dream team that will launch a clinical trial focused on stopping gastric cancer in its earliest stages. This follows SU2C's ninth roadblock fundraising special, which took place in Nashville on October 28, 2025, uniting country music and cancer research, and featured artists including Jelly Roll, the Jonas Brothers, Cece Winans, and Dan + Shay.
Similar Companies
Subscribe for full access to Stand Up To Cancer's profile
Stand Up To Cancer offers products in the media and telecoms services industry. Stand Up To Cancer's product portfolio comprises of content rights.
Subscribe for full access to Stand Up To Cancer's products in full detail
Stand Up To Cancer's revenues were less than $50M in 2023. All the revenue comes from entertainment rights and distribution.
Subscribe for full access to Stand Up To Cancer's revenue in full detail
Subscribe for full access to Stand Up To Cancer's products in full detail 
